A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
for Chronic Lymphocytic Leukemia
Drug: Venetoclax
32 locations incl. Tucson
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT06428019·Phase 3·Recruiting